Q-omics provides the consensus-scored POTEB3 profile across patient tissues and cancer cell-line models. POTEB3 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, POTEB3 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, POTEB3 RNA expression shows 8,016 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight PAAD, PRAD, and COAD as cancer lineages where POTEB3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEB3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEB3 survival associations across molecular data types. POTEB3 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEB3 RNA expression–survival associations across cancer types. High POTEB3 expression shows unfavorable associations in PAAD, KICH, LIHC, STAD, READ and LUSC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for POTEB3 RNA expression.
This table summarizes POTEB3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for POTEB3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEB3 shows higher tumor expression in PRAD. The PRAD box plot shows higher POTEB3 RNA expression in tumor versus normal tissue (log2 FC = +0.051, t-test p = .007).
This table shows molecular features associated with POTEB3 in patient tissues and cancer cell lines. In patient samples, POTEB3 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEB3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
